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Background: In our previous study, parathyroid hormone-like hormone (PTHLH) which encodes parathyroid
hormone-related protein (PTHrP) was revealed to be up-regulated in oral squamous cell carcinoma (OSCC)
compared with paired apparently normal surgical margins using microarray method. However, the function and
prognostic indicators of PTHLH/PTHrP in OSCC remain obscure.
Methods: The mRNA levels of PTHLH and its protein levels were investigated in 9 OSCC cell lines and in 36 paired
OSCC specimens by real-time PCR and western blotting. The biological function of PTHLH/PTHrP was investigated
using small interfering RNA (siRNA) in 3 OSCC cell lines, and immunohistochemistry was used to estimate the
prognostic value of PTHrP in 101 patients with head and neck squamous cell carcinoma (HNSCC), including OSCC
and oropharyngeal squamous cell carcinoma. Cell cycle was tested by flow cytometry and cell cycle related genes
were investigated by western blotting and immunocytochemistry assay.
Results: This study showed that the mRNA and protein levels of PTHLH in 9 OSCC cell lines were much higher
than that in normal epithelial cells (P < 0.0001). In 36 paired OSCC tissues, PTHLH mRNA expressions were found
higher in 32 OSCC tissues than that of paired apparently normal surgical margins (P = 0.0001). The results revealed
that the down-regulation of PTHLH/PTHrP by siRNAs could reduce cell proliferation and inhibit plate and soft agar
colony formation as well as affect the cell cycle of OSCC cells. The key proteins related to the cell cycle were
changed by anti-PTHLH siRNA. The results showed that cyclin D1 and CDK4 expressions were significantly reduced
in the cells transfected with anti-PTHLH siRNA. On the other hand, the expression of p21 was increased. The results
also showed that high PTHrP level was associated with poor pathologic differentiation (P = 0.0001) and poor
prognosis (P = 0.0003) in patients with HNSCC.
Conclusions: This study suggests that PTHLH/PTHrP is up-regulated in OSCCs. Therefore, PTHLH/PTHrP could play a
role in the pathogenesis of OSCC by affecting cell proliferation and cell cycle, and the protein levels of PTHrP might
serve as a prognostic indicator for evaluating patients with HNSCCs.
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Head and neck cancer (HNC), the sixth-most common
cancer in the world, seriously harm to the human health.
The global incidence of HNC has increased recently,
according to the report; more than 500,000 individuals
were involved each year [1,2]. Oral cancer is the most
common HNC and oral squamous cell carcinoma (OSCC)
account for >80% of HNC. Along with a further under-
standing of the pathogenesis of OSCC and improved
treatment, the survival rates of OSCC have improved over
the past ten years; however, about 50% of patients still
died of this disease within five years after diagnosis [3].
OSCC is often seriously threatened to human health
because of its fast progression and the particular
disease site. As is known, similar to other tumors, the
pathogenesis of OSCC is a complicated process. Many
factors, such as physical factors, chemical factors,
immunity of the individual and so on, are involved in
the pathogenesis of OSCC. With the development of
modern molecular biological techniques, many genes,
such as the oncogene C-myc and tumor suppressor
gene p53, have been found to be abnormally expressed
in OSCC [4,5]. Moreover, in our previous studies, we
found that the MAL gene and TGM3 gene were down-
regulated in OSCC [6,7]. And it has been reported that
matrix metalloproteinases (MMPs) expression in oral
tongue cell carcinoma were much higher than those in
normal oral mucosa [8]. Recently, it has also been re-
vealed that many cytokines and hormones participate
in the development of cancer [9,10]. We can preliminary
estimate the prognosis of OSCC based on the expression
of these genes, but so far, there is still no ideal indicator to
predict the prognosis for patients with OSCC. By studying
the function of tumor-related genes, we not only reveal
their roles in OSCC development but also evaluate the
powers to predict the prognosis of patients with OSCC.
In our previous study, parathyroid hormone-like hor-
mone (PTHLH) was found to be up-regulated 2.5-fold
in 22 pairs of OSCCs compared with the apparently
normal surgical margins through screening and oligo-
nucleotide microarray analysis [11], which suggests that
PTHLH may play an important role in the development
of OSCC. Unlike parathyroid hormone (PTH), which is
secreted only by the parathyroid gland, PTHrP, the protein
encoded by PTHLH, is expressed and secreted by a few
normal tissues and many tumor cells in an autocrine or
paracrine way. The circulating concentrations of PTHrP
are low or undetectable in normal tissues [12]. The first
eight amino acids of PTHrP and PTH are the same, that is
to say, PTHrP is a protein with N-terminal homology
to PTH. PTHrP has the ability to combine and activate
the PTH/PTHrP receptor in bone and, consequently, is
a potent stimulant of osteoclasts and osteoblasts [13].
The expression of PTHrP had been studied in humanendometrial stromal cells, and PTHrP has been shown
to stimulate the proliferation of endometrial stromal
cells in vitro [14,15]. It also had been revealed that cer-
tain doses of PTHrP not only relaxed vascular/nonvas-
cular smooth muscle and oscillated blood flow but also
regulated trans-epithelial calcium transport in various
tissues [16,17]. In a recent study, it was found that
PTHrP was up-regulated in many tumors and was respon-
sible for paraneoplastic syndromes such as hypercalcemia
in malignancy [18]. According to the literatures, PTHrP
produced by cancer cells plays an important role in the
development of bone metastases and hypercalcemia in
breast and lung cancers [19,20]. More recently, it was sug-
gested and confirmed by several studies that PTHLH/
PTHrP might contribute to the proinflammatory cytokine
cascade, resulting in elevated serum cytokines such as
interleukin-6 and tumor necrosis factor [21,22]. Thus,
PTHrP imbalance is implicated in the pathogenesis of
cancer. However, the local biological function of PTHLH/
PTHrP has not been reported in OSCC, and it remains
unclear whether PTHrP can be used as a valuable prog-
nostic biomarker for patients with OSCC.
In this study, to verify the role of PTHLH/PTHrP in
OSCCs, the expression of PTHLH mRNA and PTHrP
protein was measured in 9 OSCC cell lines and 36 OSCC
tissues compared to the expression in normal primary oral
epithelial cells and paired apparently normal surgical
margins, respectively, using real-time PCR and western
blotting. The biological function of PTHLH/PTHrP in
OSCC was observed by knocking down PTHLH/PTHrP
expression in the WSU-HN6, HN13 and CAL-27 cell
lines. Furthermore, immunohistochemistry was used to
evaluate the correlation between the PTHrP expression
level and prognosis as well as clinical parameters. The
data initially suggested that PTHLH could play an onco-
genic role in the pathogenesis of OSCC and PTHrP could
serve as a valuable prognostic indicator for OSCC.
Methods
Cell culture
The OSCC cell lines WSU-HN4, HN6, HN12, HN13
and HN30 (obtained from the University of Maryland
Dental School, USA) and CAL-27 (provided by the
American Type Culture Collection, USA) that were
used in this study were cultured in Dulbecco’s Modified
Eagle medium (DMEM) with 10% fetal bovine serum
(FBS) (GIBCO-BRL, USA), streptomycin (100 μg/ml) and
penicillin (100 units/ml). Normal epithelial cells of gin-
gival tissues which taken from the patients with impacted
teeth extraction were cultured in KSF (keratinocyte serum-
free medium; GIBCO-BRL) with 0.2 ng/ml rEGF (recom-
binant epidermal growth factor; Invitrogen, USA). The
SCC-4, SCC-9 and SCC-25 cell lines (purchased from the
American Type Culture Collection, USA) were cultured in
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10% FBS, streptomycin and penicillin (the concentrations
were the same as above). All cell lines were cultured in a
humidified, 5% CO2 incubator at 37°C [23].
Patients and specimens
In this study, pairs of samples were obtained from 36
patients who were first diagnosed with OSCC and had
not undergone any treatment before visiting our hos-
pital between 2008 and 2009. Upon obtaining the can-
cerous tissues and apparently normal surgical margins,
the samples were immediately placed in liquid nitrogen
to prevent RNA degradation. The diagnosis of each
sample was confirmed before the extraction of total
RNA and proteins. The tissue microarray samples were
obtained from paraffin-embedded tissue of 101 patients
with head and neck squamous cell carcinoma (HNSCC)
who had undergone surgical treatment when first diag-
nosed with OSCC or oropharyngeal squamous cell carcin-
oma (OPSCC) between 1989 and 1993. In this study, the
sample macrodissection has not been performed. The pa-
tients involved in this study were required to be primary
HNSCC and no distant metastases. And the patients who
accepted any treatments such as radiotherapy, chemo-
therapy and/or medicinal treatment were ruled out. The
detailed information on those 101 patients was obtained
to analyze the correlation between the expression levels
of PTHrP and clinical parameters. Of 101 patients with
HNSCC, the rest 99 patients had complete clinical in-
formation excepting 2 patients without follow-up data.
Samples were stained with hematoxylin and eosin to
analyze the pathological differentiation and pathological
diagnosis which were confirmed by two experienced pa-
thologists. In this study, pathological differentiation and
clinical stage were respectively determined according to
World Health Organization Classification of Tumors
and the TNM classification system of the International
Union Against cancer (1988). The patients involved in
this study signed a written informed consent, and the
work was approved by the Medical Ethics Committee of
the Ninth People’s Hospital, Shanghai Jiao Tong University
School of Medicine.
Immunohistochemistry and immunocytochemistry
The tissues were fixed with formalin and embedded in
paraffin then cut into 4 μm sections. The tissue sections
were then deparaffinized in xylene and rehydrated in
graded ethanol. For antigen retrieval, the samples were
heated with citrate buffer for 15 minutes. The samples
were then incubated with rabbit polyclonal PTHrP
antibody (1:150; Bioworld, USA) or rabbit polyclonal
p16 antibody (1:200; Proteinteck Group, USA) at 4°C
overnight followed by incubation with a biotinylated
secondary antibody and staining with Diaminobenzidine(DAB) (Dako, Denmark). The staining index was quan-
titatively divided into scores of 0, 1, 2, and 3 according
to the intensity of staining. In this study, the scores
representing the percentage of positive epithelial cells
were obtained and expressed as 0-100% and were ana-
lyzed by two experienced pathologists. The total scores
were obtained by multiplying the staining index by the
percentage of positive epithelial cells [24]. The expres-
sions of PTHrP were divided into high and low levels
based on a median score of 2.55 which was the cutoff
value for determining the PTHrP low or high expression.
Thus, a value <2.55 was considered low expression, and a
value ≥2.55 was considered high expression. For immuno-
cytochemistry, cells were fixed by 4% paraformaldehyde
and incubated with 0.1% Triton X-100 for 10 minutes,
then stained with primary antibody and anti-rabbit sec-
ondary antibody, followed by stained with chromogenic
agent DAB.RNA extraction
Total RNA was isolated from cell lines and frozen tissue
samples using TRIzol reagent (Invitrogen, USA) according
to the manufacturer’s instructions. The concentration and
purity of the total RNA were measured by optical density
measurements at 260 nm and 280 nm. The RNA was then
stored at -80°C or converted to cDNA using SuperScript
II reverse transcriptase (Takara, Japan) [25].Real-time polymerase chain reaction analysis
The real-time PCR reactions were accomplished using
the ABI 7300 real-time PCR system (ABI, USA) with the
SYBR Premix E × Tap reaction kit (Takara, Japan).
Real-time PCR amplification was performed in a vol-
ume of 20 μl that included 1 μl of cDNA template,
10 μl of SYBR Premix E × Tap, 0.4 μl of ROX Reference
Dye, 0.4 μl each of the forward and reverse primers
and 7.8 μl of sterile distilled water. The following primers
were used to amplify human PTHLH: the forward primer
was 5’-CGTCTCCACCTTGTTAGTTTCC-3’ and the re-
verse prime was 5’-GCAGAAATCCACACAGCTGA-3’;
the following primers were used to amplify β-actin: the
forward primer was 5’-CCTGGCACCCAGCACAAT-3’
and the reverse primer was 5’-GGGCCGGACTCGTCA-
TACT-3’. The real-time PCR program was carried out
according to the instructions of the SYBR Premix E × Tap
reaction kit. The results were analyzed using the 2-ΔΔCt
method; ΔCt was the difference between the Ct values of
the target gene and the Ct values of β-actin, and ΔΔCt
was the difference between the ΔCt of the OSCC samples
minus the ΔCt of the apparently normal surgical margins.
The results then indicated the relative expression of
PTHLH in the OSCC samples compared with that of the
apparently normal surgical margins [26].
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The cells were washed two times with cold phosphate-
buffered saline (PBS) before harvesting and then lysed in
sodium dodecyl sulfate (SDS) lysis buffer (Beyotime,
China) containing complete protease inhibitors (Roche
Bioscience, USA). Once the cells were completely lysed,
the proteins were boiled, and their concentrations were
analyzed using the Pierce BCA Protein Assay kit (Thermo
Scientific, USA). Similar quantities of total proteins were
electrophoresed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and then transferred to
a 0.22-μΜ polyvinylidene fluoride (PVDF) membrane,
which was blocked with non-fat milk for 1 hour at room
temperature followed by incubation with primary anti-
body for 2 hours at room temperature. The membrane
was then washed 3 times with PBS supplemented with
0.1% Tween-20 for 10 minutes each, and anti-mouse/
rabbit secondary antibodies were used to detect specific
immunoreactivity [27]. In this study, the rabbit polyclonal
antibody against PTHrP was used (Bioworld, USA); and the
rabbit polyclonal Cyclin D1 (CCND1) antibody (1:5000;
Clone EPR2241, Epitomics Inc., USA), the rabbit poly-
clonal p21 antibody and the rabbit polyclonal CDK4
antibody were used (1:1000; Proteintech Group, USA).
The mouse monoclonal β-actin (1:5000; Sigma-Aldrich,
USA) served as a loading control.
Small interfering RNA transfection
Small interfering RNAs (siRNA) specific for PTHLH were
designed and chemically synthesized by Biomics Bio-
technologies Co., Ltd. In this study, the sequence for the
human PTHLH siRNA (HS-PTHLH-si; abbreviated as
P-si) was 5’-GACGAUUCUUCCUUCACCAdTdT-3’. The
scrambled siRNA was also obtained from Biomics Bio-
technologies Co., Ltd. The OSCC cell lines were cultured
in 6-well cell culture plates and transfected using Lipofec-
tamine 2000 (Invitrogen, CarIsbad, USA) according to the
manufacturer’s protocol.
Cell proliferation assay
The OSCC cell lines that were transfected with the
PTHLH siRNAs were transferred to triplicate wells of a
96-well cell culture plate at a density of 1 × 103 cells/well.
To analyze the differences in the optical densities (ODs)
of the cell lines transfected with P-si or scrambled siRNA,
a CCK-8 kit was used (Dojindo, Japan). The OD value was
read at 450 nm 2 hours after CCK-8 was added following
the kit instructions, and the cell viability was measured at
intervals of 24 hours [28].
Cell cycle analysis
The cells were cultured overnight in DMEM without
serum after transfection with the siRNAs for 24 hours,
replaced with DMEM containing 10% FBS for 24 hoursand then harvested. The cells were then washed twice
with cold PBS and fixed in cold 70% ethanol overnight
according to the instructions of BD Company. The fixed
cells were gently washed twice with cold PBS and stained
with PI staining buffer for 30 minutes at 4°C in the dark.
Finally, the cell cycle was analyzed by flow cytometry [24].
Plate colony formation assay
siRNA-transfected cells (1 × 103) were cultured with
DMEM supplemented with 10% FBS in 10 cm culture
dishes for two weeks. The cell colonies were washed
twice with PBS and fixed with paraformaldehyde for
30 minutes. Then, the cells were stained with 0.1%
Coomassie Brilliant Blue R-250 (Thermo scientific,
USA) for more than 2 hours [29]. The colony formation
assay was performed according to the size and density of
the colonies to evaluate the proliferation of cells trans-
fected with the siRNAs. In this study, 3 independent ex-
periments were represented the colony formation ability.
Soft agar colony formation assay
Twenty-four hours after cells transfected with siRNA,
3 × 103 siRNA transfected cells were mixed with 0.5 ml
of 0.5% agarose in DMEM with 10% FBS, then seeded
on the top of solidified 1% agarose in 24-well plate in
triplicates. The gel was covered with 200 μl of DMEM
medium after the top layer was solidified, added 50 μl
DMED medium every week to prevent the gel drying. The
gels incubated for 3-4 weeks until the colonies formed ob-
viously, then colonies >0.1 mm in diameter were counter
under a microscopic field at × 20 magnification. 3 inde-
pendent experiments were finished in this study.
In situ hybridization (ISH)
Human papilloma virus (HPV) 16 and 18 was detected
by in situ hybridization according to the instruction of
Human papilloma virus (16/18) detection kit (Triplex
International Bioscience, China). Briefly, 4 μm tissue
sections were deparaffinized in xylene and rehydrated
in graded ethanol. Then, the samples were heated with
hybrid enhanced buffer for 30 minutes, the slides were
hybridized with a biotinylated HPV16/18-type-specific
probe and degenerated for 5 minutes at 95°C, followed by
being incubated for 16 hours at 37°C in situ hybridization
heater. Then incubated in order with reagent A, B and C
(Triplex International Bioscience, China) at 37°C and
stained with chromogenic reagent DAB (Triplex Inter-
national Bioscience, China).
Statistical analyses
In this study, the results of the real-time PCR, cell prolifer-
ation assays, cell cycle assays, colony formation assays
were compared using student’s t-test. One-way analysis of
variance (ANOVA) was used to compare three groups.
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expression and overall survival. The Cox proportional
hazards model was used for univariate and multivariate
analyses of the prognosis of patients. In this study, all
computation was accomplished using SPSS software 11.0
and GraphPad Prism, and all statistical tests were two-
sided. P < 0.05 was considered statistically significant.
Results
PTHLH/PTHrP was up-regulated in OSCC specimens and
cell lines
To determine if PTHLH/PTHrP was up-regulated in
OSCC, the PTHLH mRNA levels were investigated in
36 paired OSCC specimens using real-time PCR. The
results showed that PTHLH was up-regulated in 88.9%
(32/36) of OSCC tissues compared with the apparently
normal surgical margins (P = 0.0001) (Figure 1A). Then,
western blot analysis was used to analyze the PTHrP
protein levels in 5 representative paired OSCC specimens
and further confirmed that PTHrP was up-regulated in
OSCC specimens (Figure 1B). Moreover, we analyzed theFigure 1 PTHLH mRNA and PTHrP protein expression in OSCC specim
paired OSCC specimens including cancerous tissues and apparently norma
0.0817 ± 12.010 vs. Mean ± SE: 7.376 ± 1.040, rang: 0.988 ± 20.873; P = 0.0001
determined in 5 representative paired OSCC specimens by western blotting
(C) PTHLH mRNA levels were determined in 9 representative OSCC cell line
Figure 1A using real-time PCR (P < 0.0001; One-way ANOVA). (D) PTHrP pro
primary normal epithelial cells using western blotting.PTHLH mRNA and PTHrP protein levels in OSCC cell
lines and primary normal epithelial cells. These results re-
vealed that the PTHLH mRNA and PTHrP protein levels
were up-regulated in all 9 OSCC cell lines compared with
the normal epithelial cells (P < 0.0001) (Figure 1C, D).
Down-regulation of PTHLH/PTHrP could inhibit cell
proliferation and colony formation
Based on the results showing that PTHLH/PTHrP was
up-regulated in all 9 OSCC cell lines, siRNAs were used
to analyze the biological function of PTHLH/PTHrP in
OSCC cell lines in vitro. Three cell lines, WSU-HN6,
HN13 and CAL-27, were transiently transfected with
siRNAs (Figure 2A), and the results showed that the
growth of cells transfected with P-si was obviously
reduced compared to that of cells transfected with
scrambled siRNA (Figure 2B). This data implied that
the overexpression of PTHLH/PTHrP in OSCC cell
lines promoted cell proliferation. Considering PTHLH/
PTHrP could affect cell proliferation in vitro, plate
colony formation assays and soft agar colony formationens and cell lines. (A) PTHLH mRNA expression was analyzed in 36
l surgical margins using real-time PCR (Mean ± SE: 2.618 ± 0.495, rang:
; two-tailed Student’s t-test). (B) PTHrP protein expression was
analysis (N, apparently normal surgical margin; C, cancerous tissue).
s, primary normal epithelial cells and normal tissues showing in
tein levels were determined in 9 representative OSCC cell lines and
Figure 2 The effect of PHTLH/PTHrP on cell proliferation and colony formation. (A) PTHrP protein expression was confirmed in WSU-HN6,
HN13 and CAL-27 cell lines transfected with anti-PTHLH siRNA P-si or scrambled siRNA using western blotting. (B) Cell proliferation of WSU-HN6,
HN13 and CAL-27 cell lines transfected with anti-PTHLH siRNA P-si or scrambled siRNA were analyzed using the CCK-8 kit, each point showed the
mean values of triplicate wells (Mean ± SE). (C) Plate colony formation of WSU-HN6, HN13 and CAL-27 cell lines transfected with anti-PTHLH siRNA
P-si or scrambled siRNA was analyzed. (D) Soft agar colony formation assay was analyzed between the cell lines transfected with anti-PTHLH P-si
and cell lines transfected with scrambled siRNA.
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The efficiency of plate colony formation results indicated
that there was a significant difference between the cell
lines transfected with P-si and those transfected with the
scrambled siRNA, the colony number of the former was
obviously less than that of the latter (Figure 2C). Soft agar
colony formation assay also showed that colonies of cells
transfected with P-si were much less and smaller than that
of cells transfected with scrambled siRNA (Figure 2D).
The results, to some extent, further confirmed that down-
regulation of PTHLH/PTHrP could reduce the cell prolif-
eration of OSCC cell lines.
Down-regulation of PTHLH/PTHrP blocked the cell cycle
of OSCC cell lines
To explore the underlying mechanism for the reduc-
tion of cell proliferation and colony formation due todown-regulation of PTHLH/PTHrP, the cell cycles of
WSU-HN6, HN13 and CAL-27 cells transfected with
P-si or scrambled siRNA were analyzed and assessed
by flow cytometry. The results showed that the fractions
of P-si transfected WSU-HN6, HN13 and CAL-27 cells in
G1 phase were increased to 49.55%, 55.80% and 53.19%,
respectively compared to the corresponding cells trans-
fected with scrambled siRNA (39.22%, 38.40% and 39.80%,
respectively) (P < 0.05) (Figure 3A). This result suggested
that down-regulation of PTHLH/PTHrP reduced the cell
proliferation index of the OSCC cell lines.
To further confirm that PTHLH/PTHrP affects the
cell cycle of OSCC cell lines, key proteins related to the
cell cycle in cells transfected with P-si or scrambled siRNA
were measured by western blotting and immunocyto-
chemistry. The results showed that Cyclin D1 (CCND1)
and CDK4 were significantly reduced in the cell lines
Figure 3 (See legend on next page.)
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Figure 3 The impact of PTHLH/PTHrP on the cell cycle. (A) Cell cycle was analyzed in WSU-HN6, HN13 and CAL-27 cell lines transfected with
anti-PTHLH siRNA P-si or scrambled siRNA. (B) The proteins of Cyclin D1, CDK4 and p21 which related to cell cycle were determined in WSU-HN6
and HN13 cell lines transfected with anti-PTHLH siRNA P-si or scrambled siRNA. (C) The fold change in western blot (Figure B) was quantified and
analyzed. (D) Immunocytochemistry staining of cells transfected with PTHLH-siRNA was used to analyze the expression of PTHLH, Cyclin D1, CDK4
and p21.
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of p21 was increased (Figure 3B, C, D). These results indi-
cated that down-regulation of PTHLH/PTHrP inhibited
cell proliferation and colony formation by blocking the
cell cycle of OSCC cells at G1 phase in vitro. These pre-
liminary results indicated that the overexpression of
PTHLH/PTHrP played a key role in the pathogenesis of
OSCC.
The overexpression of PTHrP was associated with poor
pathological differentiation and poor overall survival in
patients with HNSCC
To further analyze the clinical significance of the over-
expression of PTHLH/PTHrP in patients with HNSCC,
the expression of PTHrP was measured using a tissue
microarray containing 101 HNSCC specimens and 10
normal tissues by means of immunohistochemistry.
Excepting for 6 patients were taken off the pieces in
the process of IHC and 2 patients had no follow-up
data, 64 patients survived and 29 patients died in the
rest of 93 patients. The follow-up time was from
1 month to 122 months with the median follow-up
time of 84 months. PTHrP proteins were expressed in
the cytoplasm to different degrees in HNSCC speci-
mens. The expression of PTHrP in HNSCC tissues was
much higher than in normal epithelial tissues. More-
over, the highest PTHrP protein staining of all speci-
mens was observed in poorly differentiated HNSCCs. The
results showed that the PTHrP expression level was posi-
tively correlated with pathological differentiation: the
poorer the pathological differentiation, the stronger
the PTHrP protein staining in the 93 HNSCC speci-
mens (P = 0.0001) (Figure 4A). The analysis showed no
significant differences between the PTHrP expression
and age, gender, TNM classification, lymph node me-
tastasis and the site of the disease (Table 1). The over-
all survival probability of the 93 HNSCC patients was
analyzed using Kaplan-Meier and Cox proportional
hazards regression models. The results showed that
patients with highly expressing PTHrP had poorer
survival than those with low PTHrP expression (p =
0.0003) (Figure 4B). The univariate and multivariate Cox
proportional hazards regression models showed that not
only pathological differentiation but also the PTHrP ex-
pression level could serve as an independent indicator of
prognosis for patients with HNSCC (Table 2).Positive of HPV16/18 DNA and p16 expression in HNSCCs
For ISH analysis, positive for HPV16/18 was defined if
the tumor nuclei were stained. Of the 93 HNSCC sam-
ples, 2 cases were positive for the HPV16/18 type and
p16 overexpression which detected in both the tumor
nuclei and the cytoplasm (Figure 4C). These two pa-
tients were both female and with tumors located in
base of tongue, the age of 2 patients with HPV-positive
HNSCC were respectively 41 and 42 years old. Both of
them had no history of smoking and alcohol, and the
follow-up time was both 84 months. These data were
consistent with the results that HPV16/18 was an
important etiologic factor especially for oropharyngeal
SCC, and HPV-related HNSCC was more frequent in
younger patients with no exposure of tobacco and
alcohol [30,31].
Discussion
PTHLH, which is located on 12p12.1-11.2, is produced
by a variety of normal tissues and many normal cells,
such as endometrial stromal cells [32]. This gene is re-
sponsive to changes based on the extracellular calcium
concentration, and it plays important roles at local
sites, such as bone, teeth and mammary glands [33]. It
has been reported that the expression of PTHrP was
regulated by CaR signaling in normal epithelial and
cancer cells. According to that report, PTHrP played
an important role in the regulation of calcium metabolism
in fish and pituitary-related tumors as well as cell lines
[34]. The expression of PTHrP was first identified in a
lung cancer cell line in 1987 [35]. It was then investigated
and analyzed in other cancers and cancer-relative cell
lines, such as breast cancer, prostate cancer, ovarian
cancer and so on [36]. For example, PTHLH was found
to be up-regulated in breast cancers by genome-wide
association studies (GWAS) [37]. Lindemann reported
that PTHrP expression was regulated by transforming
growth factor β through Smad/ets synergism in MDA-
MB-231 breast cancer cells [38], but in MCF-7 breast
cancer cells, it was shown that PTHrP appeared to
function as a osteolytic factor associated with breast
cancer metastases via the Smad and MAPK (Mitogen-
activated Protein Kinase) signaling pathways [39]. In
breast cancers, PTHrP produced by cancer epithelial
cells in an autocrine or paracrine manner could induce
the local osteolysis that led to the hypercalcemia of
Figure 4 The clinical significance of PTHrP overexpression was analyzed in 93 patients with HNSCCs. (A) PTHrP expression was detected
in poorly differentiated, moderately differentiated and well differentiated specimens and in normal epithelial specimens, as shown by
immunohistochemistry. (B) Kaplan-Meier survival curves illustrating the overall survival of 93 patients with HNSCC according to the PTHrP protein
levels. (C) Two patients with base of tongue squamous cell carcinoma in this study were positive for HPV16/18 and p16 expression using ISH and
IHC methods.
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that PTHrP and its receptor was highly expressed in
primary prostate cancer and played a role in the patho-
genesis of bone metastases [41]. In 2005, Kornberg et al.
found that PTHLH was up-regulated by interrogation
of Affymetrix Gene Chip Arrays and further confirmed
by real-time PCR and IHC in OSCC [42]. Yamada et al.
found that PTHrP was abundantly detected in most of
quiescent oral cancer cells and significantly up-regulated
by EGF stimulation via ERK and p38 MAPK, and found
that PTHrP contributed to the malignancy of oral
cancers, for example cell proliferation, migration and
invasiveness [43]. In addition, Trivedi et al. found that
PTHrP expression was associated with percentage of
tumor cells in metastatic lymph nodes from patients
with HNSCC [44]. In another work, it was shown that
PTHrP affected the growth and vascularity of malignant
tumors [45].In our present study, we found that the PTHLH mRNA
and PTHrP protein levels were up-regulated in nearly
88.9% of OSCCs and in all 9 OSCC cell lines compared
with the apparently normal surgical margins and normal
epithelial cells, respectively. This finding was consistent
with other reports showing that PTHLH/PTHrP was over-
expressed in many types of cancer, such as breast cancer,
esophageal cancer and prostate cancer. Furthermore, this
result also verified our previous result showing that
PTHLH was up-regulated in OSCC specimens, which
indicated that PTHLH/PTHrP might play a role in the
pathogenesis of OSCC. Currently, it is still unclear
how PTHLH/PTHrP influences cancerous cells, in par-
ticular, the biological function of PTHLH/PTHrP in
OSCC remains unclear. In this study, we found that
down-regulation of PTHLH/PTHrP by RNA interfer-
ence could inhibit cell growth and colony formation
in vitro. Both cell growth curves and colony formation
Table 1 Demographic characteristics of the patient
population by PTHrP expression




<60y 54 (58%) 2.757 ± 0.391 0.6775a
≥60y 39 (42%) 2.723 ± 0.391
Gender
Male 49 (52.7%) 2.353 ± 0.459 0.5592a
Female 44 (47.3%) 2.283 ± 0.633
Smoking history
No 62 (66.7%) 2.706 ± 0.460 0.5850a
Yes 31 (33.3%) 2.754 ± 0.352
Alcohol history
No 74 (79.6%) 2.755 ± 0.382 0.4071a
Yes 19 (20.4%) 2.671 ± 0.436
TNM stage
I/II 48 (51.6%) 2.380 ± 0.558 0.7570a
III/IV 45 (48.4%) 2.346 ± 0.515
Disease site
Tongue 64 (68.8%) 2.348 ± 0.540 0.4972b
Base of tongue 7(7.5%) 2.407 ± 0.480
cheek 11(11.8%) 2.231 ± 0.514
gingiva 9(9.7%) 2.478 ± 0.607
Orthers (lip, floor of mouth) 2 (2.2%) 2.732 ± 0.458
Lymph node metastasis
pN0 64 (68.8%) 2.740 ± 0.392 0.8158a
pN1-pN2 29 (31.2%) 2.761 ± 0.393
Pathological differentiation
I 54 (58.1%) 2.189 ± 0.540 0.0001a
II/III 39 (41.9%) 2.610 ± 0.434
aThese P value were analyzed by two-tailed Student’s t-test.
bThese P value were analyzed by One-way ANOVA analysis.
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cell proliferation of OSCC cell lines. More importantly,
we found that down-regulation of PTHLH/PTHrP could
block the cell cycle at G1 phase and that it could lead to
changes in cell cycle-related proteins, including down-
regulation of CCND1 and CDK4 and up-regulation of
p21, as shown by western blotting and immunocyto-
chemistry. These results suggested that PTHLH/PTHrP
could inhibit cell proliferation and reduce colony forma-
tion of OSCC cell lines by blocking the cell cycle. These
findings were in accordance with the reports showing
that PTHLH/PTHrP might act as a growth factor in
many cancers and might affect the growth of cancer
cells [38,43]. Beyond that, in this study, we found that
PTHLH gene may be directly or indirectly involved in
the regulation of cell cycle signal pathway. According tothese results, we assume that the overexpression of
PTHLH/PTHrP promotes the cell cycle of cancer cells,
resulting in accelerated progression of OSCC.
To evaluate the clinical significance of the up-regulation
of PTHrP in OSCC specimens, we found that high PTHrP
expression was positively correlated with pathological
differentiation. The expression of the PTHrP protein
gradually increased with the degree of pathological
differentiation, which was consistent with a report on
primary prostate cancer that suggested that PTHrP ex-
pression was associated with pathological differentiation
[46]. This result implied that patients with high PTHrP
expression often had a poor prognosis. In addition, overall
survival analysis revealed that high PTHrP expression was
associated with poor prognosis, and patients with high
PTHrP expression had a significantly low survival. But
in 36 paired clinical samples, we did not observed the
correlation between PTHLH mRNA expression and
pathological differentiation or other clinical features
because of the limitation of sample size and some sam-
ples had incomplete clinical information. The results
of the univariate and multivariate Cox proportional
hazards analyses both illustrated that PTHrP expression
could be used as an independent indicator of prognosis
for patients with HNSCC, which was in accordance with
reports showing that high PTHrP expression was an ad-
verse prognostic indicator of gastroesophageal carcinoma
[47] and predicted poor survival for patients with early
breast cancer [48]. However, these results were in contrast
to the 10-year prospective study of Henderson M, who
found that women with PTHrP-positive primary breast
cancers had a more favorable prognosis and fewer metas-
tases to bone and other sites than patients with PTHrP-
negative cancers [49]. This inconsistency might be caused
by different tumor types and/or the sample size. A further
study involving a much larger patient sample size is
required to evaluate this possible association.
Recently, it had been found that HPV was a major
etiologic factor for head and neck squamous cell carcinoma
especially for oropharyngeal squamous cell carcinoma
(OPSCC), and patients with positive HPV show significant
better overall survival than those with negative HPV in
those cancers [30,50,51]. High-risk HPV16 and HPV18
were the most common types in some cancers, and p16
expression was the surrogate marker for HPV positive in
such tumors [52,53]. The contribution of HPV for OPSCC
was disagreement in different countries. For example,
about 60% of the patients were positive for HPV DNA in
the United States [31]. But for Asian populations, the pro-
portion of HPV-related patients was lower compared with
Western countries. For example, Kawakami et al. reported
that HPV DNA was detected by PCR analysis in 38%
(40/104) Japanese patients with OPSCC, and p16 de-
tected by IHC was associated with HPV DNA positivity
Table 2 Univariate and multivariate Cox Regression Models for estimating the overall survival
Characteristics HR 95% CI P
Univariate analysis
Overall survival
Age (<60 y vs ≥60 y) 0.558 0.254 to 1.225 1.146
Gender (male vs female) 0.935 0.880 to 4.252 0.100
Alcohol history (nonsmoker vs smoker) 1.543 0.683 to 3.484 0.297
Smoking history (nonsmoker vs smoker) 1.481 0.699 to 3.137 0.305
Disease site 1.025 0.763 to 1.377 0.872
TNM stage 1.715 1.179 to 2.492 0.005
Lymph node metastasis (pN0 vs pN1 to pN2) 2.596 1.238 to 5.445 0.012
Pathological differentiation 2.294 1.448 to 3.634 0.001
PTHLH expression (low vs high) 0.022 0.003 to 0.159 <0.001
Multivariate analysis
Overall survival
PTHLH expression (low vs high) 0.024 0.003 to 0.180 <0.001
Pathological differentiation 2.156 1.268 to 3.666 0.005
Lymph node metastasis (pN0 vs pN1 to pN2) 1.100 0.423 to 2.861 0.845
TNM stage 1.193 0.730 to 1.949 0.482
Abbreviations: HR hazard ration, CI confidence interval, N lymphnode, TNM tumor-lymph node-metastasis classification.
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patients with OPSCC positive for HPV was 31% [54].
This inconsistency might be caused by different life habits
such as the exposure of tobacco, alcohol and HPVs. In this
study, the combined methods of ISH for HPV16/18 and
IHC for p16 were used to improve the sensitivity and reli-
ability. Of the 93 HNSCCs, 2 samples were positive for
HPV16/18 by ISH as well as p16 expression detected by
IHC. These results were in accordance with those of Xu
et al. who reported that only 3.5% HPV-related HNSCCs
in Chinese patients were detected using the HPV geno-
typing test [55]. In addition, Li et al. reported that none
of 16 tonsil cancer samples were positive for HPV
DNA in Chinese patients [56]. The lower proportion of
HPV-related patients in our study compared with the
result of Kawakami was attributed to the different site
of tumors. In Kawakami’s study, the cases were all
OPSCC including the tumors of tonsil, posterior wall,
lateral wall, base of tongue, anterior palatine arch and so
on. In our study, the most majority of cases were tongue
squamous cell carcinoma and few tumors originated in
tonsil, posterior wall, lateral wall, anterior palatine arch. In
fact, our results that HPV16/18 was positive in 2 of 7
tumors originated in base of tongue were consistent with
the results of Kawakami who found 4 tumor specimens
were positive for HPV in 13 tumors located in base of
tongue [51]. Thus it can be seen that HPV is not the im-
portant risk factor for Chinese patients with HNSCC. In
this study, Kaplan-Meier analysis showed that the HNSCC
patients with low PTHrP expression still had better overallsurvival than those of the patients with high PTHrP
expression after adjusting the HPV infectious factor.Conclusions
In this study, we found that PTHLH/PTHrP was overex-
pressed in 88.9% of OSCC tissues and in all 9 OSCC cell
lines. Down-regulation of PTHLH/PTHrP could block the
cell cycle at G1 phase, inhibit cell proliferation and reduce
colony formation of OSCC cell lines in vitro. In addition,
we found that PTHrP expression was associated with
pathologic differentiation and prognosis; to some extent, it
could function as an independent biomarker of prognosis
for patients with HNSCC. In the future, PTHLH/PTHrP
is expected to be a novel molecular target for the develop-
ment of novel therapeutic strategies.
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